Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 9, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) held through employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding movements within employee trusts and retirement plans rather than corporate financial performance.
Material Changes
The filing details specific movements in shareholdings associated with directors Dr. J.P. Garnier and Mr. J.D. Coombe through discretionary employee funds:
- US Retirement Savings Plan: On December 4, 2003, ADR holdings decreased from 18,768,654 to 18,731,003 at an average price of $45.13. On December 5, 2003, holdings increased from 18,731,003 to 18,767,462 at an average price of $44.95.
- Employee Share Option Plan: On December 8, 2003, the GSK Trust transferred 61,394 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance report regarding director interests.
Key Facts for Investor Verification
- Directors Dr. J.P. Garnier and Mr. J.D. Coombe hold potential interests in shares held by the GlaxoSmithKline US Retirement Savings Plan and the GSK Trust.
- Recent share movements in the US Retirement Savings Plan reflect fund activity rather than direct director trading, with prices fluctuating between $44.95 and $45.13.
- A transfer of 61,394 Ordinary shares occurred from the GSK Trust to employee option plan participants.